Alecensa 150MG Capsule (7’s) is a targeted therapy medication that contains Alectinib, a potent anaplastic lymphoma kinase (ALK) inhibitor. This drug is primarily used in the treatment of non-small cell lung cancer (NSCLC) that is ALK-positive, which means that the cancer cells have a specific genetic alteration that makes them susceptible to this treatment. Each capsule contains 150 mg of Alectinib, designed to inhibit the growth of cancer cells by blocking the activity of the ALK protein, which plays a crucial role in the proliferation of these cells. Alecensa is typically prescribed for patients who have previously been treated with crizotinib or for those whose cancer has progressed on this medication. The formulation is designed for oral administration, making it convenient for patients to incorporate into their daily routines. As a result, Alecensa has become an essential option in the management of advanced ALK-positive NSCLC, offering hope for improved outcomes and quality of life for patients battling this challenging disease.

Phesgo Injection (10ml) is a targeted therapy used primarily in the treatment of certain types of breast cancer, specifically HER2-positive breast cancer. This innovative medication combines two monoclonal antibodies, Pertuzumab and Trastuzumab, each at a dosage of 600mg, to effectively inhibit the growth of cancer cells that overexpress the HER2 protein. By blocking the HER2 receptor, Phesgo helps to slow down or stop the proliferation of cancer cells, making it a vital component of treatment regimens for patients with this aggressive form of cancer. The injection is administered subcutaneously, providing a more convenient option compared to traditional intravenous therapies, which can enhance patient compliance and comfort. Phesgo is typically used in conjunction with chemotherapy to maximize its effectiveness, and its formulation is designed to ensure optimal absorption and therapeutic action.